Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00522795 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00522795 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 40 participants.
The verdict
NCT00522795, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
Interventions
- DRUG PPX with cisplatin and radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00522795
The ClinicalTrials.gov registry entry for NCT00522795 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PPX with cisplatin and radiation is the first listed.
NCT00522795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00522795 about?
NCT00522795 is a clinical study titled "Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001)". Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001
What is the current status of trial NCT00522795?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00522795?
The interventions under investigation include: PPX with cisplatin and radiation (DRUG).
Who is sponsoring clinical trial NCT00522795?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.